Twenty-one children who developed therapy-related acute myeloid leukemia after treatment for acute lymphoblastic leukemia received allogeneic bone marrow transplants between January 1990 and June 1997. All had previously received epipodophyllotoxin-containing regimens and 11 had cytogenetic abnormalities involving 11q23. Induction chemotherapy was given to 13 patients and eight patients went directly to BMT. Eleven received marrow from matched siblings, eight from matched unrelated donors and two from haploidentical family members. Conditioning regimens included cyclophosphamide (CY), cytarabine, and total body irradiation. Four patients are alive disease-free between 1118 and 1825 days post-BMT resulting in a 3-year DFS of 19%. Ten patients relapsed at a median of 150 days (range 30-664 days) post-BMT and all eventually died of disease. Seven patients died of regimen-related toxicity. The outlook for patients with therapy-related AML/MDS remains poor and more effective therapy is needed. Keywords: therapy-induced acute myeloid leukemia; bone marrow transplantation; children As cure rates for cancer have improved with the development of combination chemotherapy regimens, therapyrelated acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have become more prevalent. The initial reports of AML following treatment with alkylating agent chemotherapy were published in the 1970s. Therapyrelated AML following alkylator-based chemotherapy regimens is associated with a long latency period, evolution from MDS, abnormalities of chromosome 5 or 7, and an extremely dismal prognosis.
As cure rates for cancer have improved with the development of combination chemotherapy regimens, therapyrelated acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have become more prevalent. The initial reports of AML following treatment with alkylating agent chemotherapy were published in the 1970s. Therapyrelated AML following alkylator-based chemotherapy regimens is associated with a long latency period, evolution from MDS, abnormalities of chromosome 5 or 7, and an extremely dismal prognosis. 1 More recently, development of AML following therapy with epipodophyllotoxins for acute lymphoblastic leukemia or solid tumors has been described. 2, 3 Epipodophyllotoxin-associated AML/MDS is associated with a short latency period usually without preceding MDS and abnormalities involving chromosome 11q23. 4, 5 The risk of developing this complication is related to the treatment schedule, 2,4 the cumulative dose 1 and concomitant use of other drugs such as alkylating agents or asparaginase. 6 Standard AML induction chemotherapy can induce a complete remission in 25 to 81% of patients but the duration of remission is short and survival poor. 5, 7 While some studies suggest that patients with de novo AML and t(9:11) may have a better survival than patients with other 11q23 abnormalities, 8, 9 the prognosis of therapyrelated AML patients with 11q23 is uniformly dismal. 5 As survival following chemotherapy is poor the use of allogeneic BMT is justified. However, DFS following transplant is difficult to assess as most reports of allogeneic BMT for therapy-related leukemia describe both adult and pediatric patients and include AML related to alkylating agents and epidophyllotoxins in patients with a variety of primary tumors. In addition, AML evolving from myelodysplasia is often labeled as 'secondary' AML. There are only two reports which describe the results of allogeneic BMT in pediatric patients with epipodophyllotoxin associated AML; one describing 10 patients with an original diagnosis of ALL 7 and another reporting on 10 children with previous solid tumors. 10 In this report we describe the outcome after allogeneic transplantation in a larger series of 21 children who all developed acute myeloid leukemia after previously receiving epidophyllotoxin-containing therapy for lymphoid malignancies.
Materials and methods

Patient details
We reviewed the records of children who underwent allogeneic BMT between January 1990 and July 1997 at St Jude Children's Research Hospital and identified 21 patients transplanted for secondary AML after initial diagnosis of a lymphoid malignancy. All patients had originally been treated on institutional protocols for acute lymphoblastic leukemia or lymphoma approved by the Institutional Review Board (IRB). 11 Treatment plans all included epipodophyllotoxins often in combination with alkylating agents. 6, 12 Patient details are shown in Table 1 . 
Transplant details
All patients were transplanted on IRB approved protocols. Eleven patients received marrow from matched siblings, eight from matched unrelated donors and two from haploidentical family members. All patients received cytarabine (3 g/m 2 , six doses) and cyclophosphamide (45 mg/kg, two doses) with Mesna (45 mg/kg divided into five doses) administered before and 3, 6, 9, 12 h after each dose of cyclophosphamide. 13 They also received total-body irradiation in eight fractions, for a total of 12 Gy (matched sibling marrow recipients) or 14 Gy (MUD recipients). Antithymocyte globulin was administered as part of the pre-transplant conditioning regimen to two patients to enhance immunosuppression. Marrow from the mismatched family members and from unrelated donors was depleted of approximately 1.5 logs T lymphocytes by use of anti-T cell antibodies CD6 and CD8 and rabbit complement. 13 Beginning 2 days before transplantation, both matched sibling and MUD recipients received cyclosporin A, at a dosage that was adjusted to attain plasma levels of 200-350 ng/ml. Patients given matched sibling marrow received additional GVHD prophylaxis with pentoxyphylline or short course methotrexate. Acute and chronic GVHD were graded according to standard criteria. 14 Patients with mild/moderate GVHD (grade 1 or 2) were treated with methylprednisolone (1-2 mg/kg daily). If GVHD remained at grade 2 for Ͼ7 days or progressed, the steroid dosage was increased to 5-10 mg/kg daily. One patient who had no evidence of improvement after 5 days of high-dose steroid therapy was treated with CBL-1 monoclonal antibody, as previously described. 15 
Statistics
Life tables for disease-free survival were constructed by the method of Kaplan and Meier.
Results
Patient characteristics
Demographic data for the 21 patients who underwent BMT for therapy-related AML/MDS are outlined in Table 1 . Seventeen had an initial diagnosis of ALL while in four cases the original malignancy was NHL. All patients had received epipodophyllotoxin-containing regimens as therapy for their primary malignancy and 15 had also received alkylating agents. The cytogenetic details of several patients in this report have previously been described in detail. 5 Eleven patients had translocations involving 11q23 that have previously been reported in around 70% of patients with epipodophyllotoxin-induced AML. One patient (UPN 253) was considered a possible lineage switch.
Induction therapy
Seven patients went immediately to BMT. Thirteen had received prior induction chemotherapy and five were in complete remission at the time of BMT. One patient (UPN 238) had received an autologous transplant in first remission prior to 1990, relapsed and underwent allogeneic BMT from a matched unrelated donor in second relapse of therapy-related AML.
Transplant procedure
Twenty patients engrafted with a median day to ANC of 500 of 19 (range 13-27) and one patient relapsed early post-transplant. Three patients developed grade III-IV acute GVHD. Of 13 patients evaluable for chronic GVHD only one developed extensive chronic GVHD. Seven patients died of regimen-related toxicity (Table 2 ) with one dying of GVHD, one from multisystem organ failure and five of pneumonitis or diffuse alveolar hemorrhage. There was also a high incidence of other grade III-IV toxicity in this heavily pretreated population (Table 2) . One MUD recipient developed EBV lymphoma, which responded to infusion of donor-derived EBV specific cytotoxic T lymphocytes. 16 Ten patients relapsed at a median of 150 days (range 30-664 days) post-BMT and although some received further chemotherapy or donor lymphocyte infusions, all eventually died of disease. Four patients are alive diseasefree between 1118 and 1825 days post-BMT resulting in a 3-year DFS of 19% (Figure 1 ). The cumulative risk of relapse was 68% at 3 years ( Figure 2 ). All four survivors currently have Karnofsky scores of 90-100.
Discussion
Patients who develop AML or MDS as a second malignancy generally have a poor prognosis despite intensive chemotherapy. Epipodophyllotoxin-associated AML and MDS have a particularly poor prognosis and although patients can attain remission with chemotherapy, these Days post-BMT Probability of relapse remissions are usually brief and there are few long-term survivors. The outcome after bone marrow transplant for therapy-related AML is also poor. A study from Seattle reported a 5-year DFS of 7.8% for 17 adults patients with therapy-related AML 17 while Ballen et al 18 reported 24% DFS at 3 years. For pediatric patients with epipodophyllotoxin-induced AML, Sandler et al 7 reported eight patients receiving allogeneic transplants and two patients receiving autografts after previous therapy for ALL. Only two patients were in remission at the time of the report with six relapsing and two dying of regimen-related toxicity. Another recent report described 11 children transplanted predominantly with non-TBI-containing conditioning regimens and documented significant regimen-related toxicity, a high relapse rate and a 2-year DFS of 24%. 10 The 21 children in our study with secondary AML or MDS also had a dismal outcome, with both relapse and regimen-related toxicity being important causes of mortality. The small numbers precluded any difference being detected between patients who did or did not have 11q23 abnormalities. A high regimen-related toxicity is likely a consequence of the combination of initial therapy for the lymphoid malignancy, the induction therapy for the subsequent AML and the transplant conditioning regimen. The role of induction chemotherapy prior to transplant in secondary AML has not been clearly defined. While taking patients directly to transplant avoids additional organ toxicity induced by induction chemotherapy and spares the patient infection risks, some patients need time to obtain a donor and require chemotherapy to achieve disease control. In a study reported by the Seattle group, there was no difference in relapse, non-relapse mortality, or disease-free survival between patients with secondary AML who received induction chemotherapy and those who did not. 17 This study, however, included patients with both AML following MDS and therapy-related AML, and the patients with therapy-related AML had a lower DFS and higher relapse rate regardless of whether they received induction chemotherapy. 17 Of note in our series, two of the four survivors had not received induction chemotherapy, but the numbers are too small to draw any definitive conclusions.
In view of current poor results, alternative therapies are needed to reduce both relapse and non-relapse morbidity and mortality. Intensifying conditioning is not an option in this heavily pretreated group who already have a high regimen-related morbidity and mortality. Indeed the addition of busulphan to a cyclophosphamide/TBI regimen in patients with myelodysplasia reduced relapse but increased non-relapse morbidity so that DFS was unchanged. 19 An alternative option may be to add monoclonal antibodies reactive with host hemopoietic cells to the conditioning regimen to reduce residual leukemia. 20 One other solution to the problem of regimen-related toxicity would be to evaluate the role of subablative conditioning, with donor lymphocyte infusion post-transplant. 21 There is one series that suggests graft-versus-leukemia may reduce relapse in patients with secondary AML 22 justifying exploration of immunotherapy approaches post-transplant.
